Abstract
The inflammatory response is a protective process of the body to counteract xenobiotic penetration and injury, although in disease this response can become deregulated. There are endogenous biochemical pathways that operate in the host to keep inflammation under control. Here we demonstrate that the counter-regulator annexin 1 (AnxA1) is critical for controlling experimental endotoxemia. Lipopolysaccharide (LPS) markedly activated the AnxA1 gene in epithelial cells, neutrophils, and peritoneal, mesenteric, and alveolar macrophages-cell types known to function in experimental endotoxemia. Administration of LPS to AnxA1-deficient mice produced a toxic response characterized by organ injury and lethality within 48 hours, a phenotype rescued by exogenous application of low doses of the protein. In the absence of AnxA1, LPS generated a deregulated cellular and cytokine response with a marked degree of leukocyte adhesion in the microcirculation. Analysis of LPS receptor expression in AnxA1-null macrophages indicated an aberrant expression of Toll-like receptor 4. In conclusion, this study has detailed cellular and biochemical alterations associated with AnxA1 gene deletion and highlighted the impact of this protective circuit for the correct functioning of the homeostatic response to sublethal doses of LPS.
| Original language | English |
|---|---|
| Pages (from-to) | 1607-1617 |
| Number of pages | 11 |
| Journal | American Journal of Pathology |
| Volume | 166 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2005 |
| Externally published | Yes |
Bibliographical note
Funding Information:Supported by the Arthritis Research Campaign UK (senior fellowship 15755 to M.P. ); Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP) , Brazil ( 03/11292-0 to S.M.O . and Ph.D. studentship 02/09920-0 to A.S.D. ); Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil ( 300943/1994-6 to S.M.O. ); Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazil (Ph.D. sandwich studenship BEX0223/03-4 to A.S.D. ); the Nuffield Foundation UK (Ph.D. studentship from Oliver Bird Fund to S.Y.); Wellcome Trust (principal research fellowship to R.J.F.), and the Medical Research Council UK (to F.D.A.).